TCT-648 Abstract Withdrawn  by unknown
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B265and this translated into impaired systolic left ventricular function at
6-12 months post-TAVR (p <0.01). A greater rise in CK-MB levels
independently associated with an increased 30-day, late (median of 21
[8-36]months) overall and cardiovascular mortality (p <0.001 for all).
A >5-fold rise in CK-MB levels appeared to be the optimal threshold
for associating with signiﬁcantly worse clinical outcomes (p <0.001).
CONCLUSIONS Some degree of myocardial injury was detected in
two-thirds of patients post-TAVR, especially in those undergoing TA-
TAVR. A greater rise in CK-MB levels associated with increased acute
and late mortality, imparting a negative impact on left ventricular
function. A CK-MB rise >5-fold from baseline appears to be the
optimal threshold for deﬁning clinically relevant myocardial infarc-
tion post-TAVR.
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Native Valve Calciﬁcation Degree Does Not Impact Upon Hemodynamic
Performance of an Inﬂatable and Fully Repositionable Non- Metallic
Transcatheter Aortic Valve
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1Vivantes Klinikum im Friedrichshain und Am Urban Berlin and
University Hospital Rostock, Berlin, Rostock, Germany
BACKGROUND To analyze our single center experience with trans-
catheter aortic valve implantation (TAVI) using the Direct Flow (DF)
prosthesis and address speciﬁcally the impact of native AV calciﬁca-
tion degree and distribution on prosthetic hemodynamic
performance.
METHODS A consecutive series of patients with severe symptomatic
aortic valve stenosis (AVS) were included in the present study. Data
were prospectively collected and retrospectively analyzed. Patients
were divided in 3 groups according to the amount of AV calciﬁcation
as detected at preoperative cardiac CT ( group I <20%, group II be-
tween 20-50%, and group III over 50% of the total AV area). Periop-
erative and mid-term follow-up outcomes were compared.
RESULTS A total of 116 patients were evaluated. Group I included
46%, group II 46%, and group III the remaining 8% of the patients.
Preoperative trans-AV gradient and calciﬁcation extension along the
aortic unit were signiﬁcantly higher in groups II and III (p¼0.008 and
p<0.0001) and a trend for higher logistic euro-SCORE was present in
group III (p¼0.08). Average CT perimeter derived annular diameter
was similar in the 3 groups (24.72.0; 24.92.0; 24.8 1.3 mm; p¼0.8)
and average implanted prosthesis size was also comparable (26.01.5;
25.71.5; 25.61.4; p¼0.5). No patient required conversion to con-
ventional surgery or emergent cardiopulmonary bypass support. A
total of 13 patients (11%) had a mild paravalvular leak and the
remaining patients had no or trivial regurgitation. Clinical outcomes
and hemodynamic valve performance, including trans-prosthetic
gradients, AV maximal velocity, and effective oriﬁce area, were
similar in the 3 groups at discharge and at the various stages of
postoperative follow-up. Midterm follow-up predicted survival was
88.6% in group I, 96.8 % in group II, and 80.0% in group III (Mantel-
Cox p¼0.08).
CONCLUSIONS Independently by the AV calciﬁcation distribution,
adequate valve sizing and implantation can be achieved with this
inﬂatable non-metallic prosthesis. As shown in our experience,
the DF prosthesis preserves a consistent and satisfactory hemody-
namic proﬁle even in patients with a higher native AV calciﬁcation
burden. Moreover, a trend for higher follow-up predicted mortality
should be expected in patients with higher AV calciﬁcation burden,
most probably as a result of their more complex overall comorbid
proﬁle.
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Efﬁcacy of a 1-year follow-up program conducted in a tertiary care centre
following percutaneous aortic valve implantation: the TAVI follow-up
program
Tiziana Claudia Aranzulla,1 Mauro De Benedictis,1 Innocenzo Scrocca,1
Barbara Mabritto,1 Alfredo Pizzuti,1 Emanuele Meliga,1
Maria Elena Rovere,1 Maria Rosa Conte1
1Mauriziano Umberto I Hospital, TURIN, Italy
BACKGROUND Patients undergoing transcatheter aortic valve im-
plantation (TAVI) represent an expanding subset due to population
ageing and increasing referral. Referral includes also patients initially
screened in hospitals and outpatient clinics different from those in
which procedures are eventually performed. In addition, TAVI pa-
tients are usually elderly, and often difﬁcult to manage due to
comorbidities. We aimed to examine adherence and efﬁcacy of a
surveillance program conducted in the same center where TAVI was
performed: the TAVI follow-up program (TAVI-FP).
METHODS The TAVI-FP included outpatient visits performed by
Interventional Cardiologists and contextual echocardiograms by op-
erators experienced in TAVI imaging. The ﬁrst TAVI-FP visit was
planned at discharge, usually within 3-6 months. All patients were
contacted by phone at 30 days in order to assess clinical status and
recall for TAVI-FP inclusion. Adherence to the Program did not pre-
clude, rather encouraged visits by local physicians. Not responders
were followed-up by phone calls and/or contacts with referring
physicians.
RESULTS A total of 167 TAVI were performed at our Division from
June 2008 to January 2014. All patients who survived (n¼160,
95.8%) were included in the TAVI-FP. At 13.55.9 months, death
occurred in 42 patients (26.3%), and it was due to cardiac causes in
29 (69% of all deaths). Of these, 16 (55.1%) died within the ﬁrst
year. In particular, 7 (24%) died before the scheduled TAVI-FP visit,
at 2.31.6 months, all by cardiac death. Among the remaining, 141
patients (92.2%) fulﬁlled the TAVI-FP. These patients experienced a
better outcome as compared to those who did not attend TAVI-FP
(total mortality 19.1% versus 66.7%, p¼0.001; cardiac mortality
12.8% versus 33.3%, p¼0.07), despite similar characteristics (Table).
For TAVI-FP patients therapies were progressively titrated accord-
ing to patient’s need: Beta Blockers and ACE/ Sartans were assumed
by 27.7% and 39.7% of patients at the ﬁrst TAVI-FP visit, and by
39.7% and 52.5% at the last (p 0.03 and 0.03, respectively). The
majority of TAVI-FP patients were in NYHA class I-II (91.5%) at last
contact, mean EF was 579%, IM>2 and IA>2 were found in 11.3
and 2.8%.TAVI-FPResponders Non-Respondersp(n[141) (n[12)Female gender (%) 86 (61) 8 (66.7) 0.77Age (years) 845 858 0.76
Logistic ES (%) 239 2111 0.54
Diabetes 47 (33.3) 6 (50) 0.34BPCO 47 (33.3) 5 (41.7) 0.54Neurological
Dysfunction (%)16 (11.3) 1 (8.3) 1.00Neoplasia (%) 22 (15.6) 2 (16.7) 1.00Frailty (GSS*>2) (%) 40 (28.4) 4 (33.3) 0.74Follow-up duration
(months)3018 1311 0.002Total Mortality (%) 27 (19.1%) 8 (66.7) 0.001Cardiac Mortality (%) 18 (12.8) 4 (33.3) 0.07Hospitalization 57 (40.4) 5 (41.7) 1.00CONCLUSIONS Our TAVI-FP had a high rate of adherence. Cardiac
mortality still represented the predominant cause of death, occurring
in more than 50% within the ﬁrst year. The investment of every effort
to include all TAVI patients in a centralized program may be valuable,
since in-loco availability of expertise and techniques may impact on
outcome. Finally, the high early mortality may raise the issue whether
to anticipate at 30 days the ﬁrst TAVI-FP visit in this frail and complex
population.
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